Literature DB >> 17292125

Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.

Ruchika Nijhara1, Krishna Balakrishnan.   

Abstract

Scientists and entrepreneurs who contemplate developing nanomedicine products face several unique challenges in addition to many of the traditional hurdles of product development. In this review we analyze the major physicochemical, biologic and functional characteristics of several nanomedicine products on the market and explore the question of what made them unique. What made them successful? We also focus on the regulatory challenges faced by nanomedicine product developers. Based on these analyses, we propose the factors that are most likely to contribute to the success of nanomedicine products.

Mesh:

Substances:

Year:  2006        PMID: 17292125     DOI: 10.1016/j.nano.2006.04.005

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  15 in total

1.  Translational considerations for cancer nanomedicine.

Authors:  Stephan T Stern; Jennifer B Hall; Lee L Yu; Laura J Wood; Giulio F Paciotti; Lawrence Tamarkin; Stephen E Long; Scott E McNeil
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

2.  Opsonization, biodistribution, cellular uptake and apoptosis study of PEGylated PBCA nanoparticle as potential drug delivery carrier.

Authors:  Kiran Ramanlal Chaudhari; Mukesh Ukawala; Arehalli S Manjappa; Abhinesh Kumar; Piyush Kishor Mundada; Anil Kumar Mishra; Rashi Mathur; Jukka Mönkkönen; Rayasa S Ramchandra Murthy
Journal:  Pharm Res       Date:  2011-07-09       Impact factor: 4.200

3.  Trojan pH-Sensitive Polymer Particles Produced in a Continuous-Flow Capillary Microfluidic Device Using Water-in-Oil-in-Water Double-Emulsion Droplets.

Authors:  Ane Larrea; Manuel Arruebo; Christophe A Serra; Victor Sebastián
Journal:  Micromachines (Basel)       Date:  2022-05-31       Impact factor: 3.523

Review 4.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

5.  Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.

Authors:  Hai-jiang Jin; Hao Zhang; Min-li Sun; Bai-gen Zhang; Ji-wei Zhang
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

Review 6.  Prospects and applications of nanobiotechnology: a medical perspective.

Authors:  Md Fakruddin; Zakir Hossain; Hafsa Afroz
Journal:  J Nanobiotechnology       Date:  2012-07-20       Impact factor: 10.435

7.  Effects of disciplinary cultures of researchers and research trainees on the acceptability of nanocarriers for drug delivery in different contexts of use: a mixed-methods study.

Authors:  Vanessa Chenel; Patrick Boissy; Jean-Pierre Cloarec; Johane Patenaude
Journal:  J Nanopart Res       Date:  2015-04-17       Impact factor: 2.253

Review 8.  Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors.

Authors:  Derusha Frank; Charu Tyagi; Lomas Tomar; Yahya E Choonara; Lisa C du Toit; Pradeep Kumar; Clement Penny; Viness Pillay
Journal:  Int J Nanomedicine       Date:  2014-01-22

Review 9.  Nanomaterial Databases: Data Sources for Promoting Design and Risk Assessment of Nanomaterials.

Authors:  Zuowei Ji; Wenjing Guo; Sugunadevi Sakkiah; Jie Liu; Tucker A Patterson; Huixiao Hong
Journal:  Nanomaterials (Basel)       Date:  2021-06-18       Impact factor: 5.076

10.  Analyses of Acceptability Judgments Made Toward the Use of Nanocarrier-Based Targeted Drug Delivery: Interviews with Researchers and Research Trainees in the Field of New Technologies.

Authors:  Vanessa Chenel; Patrick Boissy; Jean-Pierre Cloarec; Johane Patenaude
Journal:  Nanoethics       Date:  2015-10-29       Impact factor: 0.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.